are glp 1 drugs safe GLP-1 Safety Check Low Dose GLP-1 for Inflammation:

Obesity leads to a hypercoagulable state, increasing the risk of deep vein thrombosis and cerebral venous sinus thrombosis

The relative contribution of GIP versus GLP-1 to mediate postprandial insulin secretion has been extensively studied and appears to differ along the continuum from metabolic health to type 2 diabetes (T2D)

Side Effect Profiles The most noticeable practical difference is that dual agonists like tirzepatide tend to cause slightly more gastrointestinal side effects than pure GLP-1 agonists

is doubling down on the booming weight-loss drug race, with CEO Albert Bourla declaring the company will be a "formidable competitor" after securing a $10 billion deal to acquire obesity-drug developer Metsera

doi: 10.1016/S2213-8587(17)30092-X 60 ArodaVRBainSCCariouBPiletiMRoseLAxelsenMet al

Second, by avoiding high peak concentrations followed by deep troughs, once-daily dosing may reduce the Cmax-related gastrointestinal side effects (nausea, vomiting) that are often associated with bolus-like GLP-1 exposure while maintaining sufficient trough concentrations for efficacy